Pfizer’s Novel HIV/AIDS Treatment SELZENTRY™ Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients - Nov. 25, 2008 (Pfizer.com)
Pfizer Withdraws Application to Switch Viagra to Non-Prescription Status in Europe - Nov. 20, 2008 (Pfizer.com)
New Analysis Suggests That Improvements in Kidney Function in Patients Treated with Lipitor Strongly Correlate with a Reduced Risk of Major Cardiovascular Events - Nov. 12, 2008 (Pfizer.com)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference - Nov. 6, 2008 (Pfizer.com)
Pfizer Discontinues Development Program for Its Phase 3 Obesity Compound (CP-945,598) - Nov. 5, 2008 (Pfizer.com)
|
Greater life expectancy and changes in lifestyle are combining to create an epidemic of diabetes throughout the world. The prevalence of diabetes ranges from 5 percent of the population in North America and Europe to 10-25 percent in Asia, with more than 300 million people worldwide expected to be diagnosed with the disease by 2025. Treating diabetes and its complications, which severely compromise quality of life (blindness, pain and renal dialysis), consumes 15 percent of healthcare budgets in the U.S. 
